12 to 20 Plus acquisition
This article was originally published in The Tan Sheet
Executive Summary
Purchase of Neurochemical Research Corporation by 12 to 20 Plus announced Oct. 2. San Luis Obispo, Calif.-based firm now holds NRC's "line of technically sophisticated dietary supplements," including: ChemoKare, which possesses ingredients that "significantly inhibit and even kill human cancer cells;" QuitSystem for recovering alcoholics and drug abusers to repair "dramatically impaired brain chemistry;" and Anaplex, a "drug-free and non-herbal treatment for anxiety and depression." Three years following acquisition, combined firm expects annual sales volume to surpass $30 mil. Line will be sold under new division called Neurochemical Research Group...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.